Abstract

BackgroundMost HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). However, a subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. We evaluated CD4 T-cell proliferation among suboptimal responders and its correlation with CD4 T-cell activation.MethodsThe magnitude of CD4 increase (difference between absolute CD4 counts at baseline and absolute CD4 counts at 4 years of ART) was grouped into 4 quartiles for the 211 patients with sustained HIV-RNA viral suppression. Cases of ‘Suboptimal immune responders’ included patients within the lowest quartile [Median CD4 increase 165 (Range −43-298) cells/μl; n=52] and a comparison group of ‘Optimal immune responders’ was defined as patients within the highest quartile of CD4 increase [Median CD4 increase 528 (Range 417–878) cells/μl; n=52]. Frozen PBMC were thawed and analysed from a convenient sample of 39 suboptimal responders and 48 optimal responders after 4 years of suppressive antiretroviral therapy. T-cell activation was measured by proportions of T-cells expressing surface marker CD38 and HLADR (CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ cells). T-cell proliferation was determined by the extent of carboxyfluorescein diacetate succinimidyl ester (CFSE) dye dilution on culture day 5 of PBMCs in the presence of antigen (SEB, PPD, CMVpp65, GagA and GagD). Samples were analyzed on a FACS Calibur flow cytometer and flow data was analyzed using FlowJo and GraphPad.ResultsOverall, CD4 T-cell proliferation on stimulation with SEB, PPD, CMVpp65, Gag A and Gag D.antigens, was lower among suboptimal than optimal responders; this was significant for SEB (CD4+ p=0.003; CD8+ p=0.048) and PPD antigens (CD8+ p=0.038). Among suboptimal responders, T-cell proliferation decreased with increasing immune activation (Negative correlation; slope = −0.13±−0.11) but not among optimal responders.ConclusionT-cell immune activation and exhaustion were associated with poor proliferation among suboptimal responders to HAART despite sustained viral suppression. We recommend studies to further understand the mechanisms leading to impaired T-cell function among suboptimal responders as well as the potential role of immune modulation in optimizing CD4 count and functional recovery after HAART.

Highlights

  • Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART)

  • T-cell proliferation after day 5 of stimulation with Staphylococcal enterotoxin B (SEB), purified protein derive (PPD), GagA&D and CMVpp65 antigens Figure 3 shows our typical analysis of T-cell proliferation of Peripheral Blood Mononuclear Cells (PBMC) stained labelled with fluorescent dye 5,6carboxyfluorescein diacetate succinimidyl ester (CFSE); on day 5 of stimulation with SEB, Gag A & D, PPD and CMV antigens

  • Upon stimulation with SEB, a super-antigen, Tcell proliferation was lower among suboptimal responders than optimal responders to suppressive HAART; (CD4+ P=0.003 and CD8+P=0.048)

Read more

Summary

Introduction

Most HIV-infected subjects exhibit a progressive rise in CD4 T-cell counts after initiation of highly active antiretroviral therapy (HAART). A subset of individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia. Up to 40% of HAART-treated individuals exhibit very poor CD4 T-cell recovery despite effective control of HIV-RNA viraemia [5,6]. With the increasing number of individuals on HAART for longer period of time and with the emerging population of suboptimal responders to HAART despite viral suppression, there is need to consider CD4 T-cell function recovery as the ultimate measure of immune recovery. Our results give insight on the persistent immune dysfunction among patients that do not reconstitute their CD4 counts despite long periods of HIV-RNA viral suppression and emphasize the need for innovative immune modulation interventions to optimise immune recovery in this sub-population of HAART-treated individuals

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call